

Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')

Result of Annual General Meeting

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that at the Annual General Meeting ('AGM') held earlier today, all resolutions were duly passed on a show of hands.

The results of the proxy votes received in respect of the resolutions, given to the Chair prior to the meeting, are set out below:

Resolution		In favour	%	Against	%	Withheld
1	Ordinary	29,848,025	99.14	259,286	0.86	11,292
2	Ordinary	29,841,588	99.12	265,703	0.88	11,312
3	Ordinary	29,798,308	99.12	265,907	0.88	54,388
4	Ordinary	25,110,831	98.94	268,264	1.06	4,739,508
5	Ordinary	29,815,967	99.11	268,125	0.89	34,511
6	Ordinary	29,798,268	99.12	265,937	0.88	54,398
7	Ordinary	29,818,181	99.12	265,904	0.88	34,518
8	Ordinary	29,846,958	99.14	260,338	0.86	11,307
9	Ordinary	29,846,728	99.13	260,576	0.87	11,299
10	Ordinary	29,670,496	98.66	401,629	1.34	46,478
11	Special	29,652,870	98.54	439,135	1.46	26,598
12	Special	29,847,337	99.14	259,935	0.86	11,331

Notes:

1. A "Vote withheld" is not counted in the calculation of the percentage of shares voted "In favour" or "Against".
2. As at 21 July 2025, being the voting deadline date in respect of the Annual General Meeting, the total number of Ordinary Shares of 0.1p each in issue and the total number of voting rights was 71,395,635.

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 27 June 2025.

For more information:

Tissue Regenix Group plc
Daniel Lee, Chief Executive Officer
David Cocke, Chief Financial Officer

www.tissueregenix.com
via Walbrook PR

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Edward Whitley
Nigel Birks - Life Science Specialist Sales
Harriet Ward - ECM

Tel: +44 (0) 20 7466 5000

Walbrook PR (Financial PR and IR)
Alice Woodings

Tel: +44 (0)20 7933 8780
TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

